ThinkPatternGet the app
Story
TECHNOLOGY · NOV 19, 2026

Anthropic Launches Claude Science Amid AI Drug Discovery Surge

Anthropic launched Claude Science and went public as major pharmaceutical firms report AI is cutting early-stage drug discovery timelines by up to half.

Artificial intelligence is significantly accelerating early-stage drug discovery, with major pharmaceutical companies reporting that the time to produce new molecules has been cut by as much as half. Novartis reduced its average project-to-candidate timeline from three years to between 18 and 24 months, while Sanofi saved at least one year in developing an asthma treatment. AstraZeneca has integrated AI across its entire discovery and development pipeline to identify therapeutic targets and safety risks.

Anthropic has positioned itself as both a collaborator and a competitor in the sector, launching its own laboratory and scientific software, Claude Science, alongside a $1.5 trillion initial public offering. The company has partnered with six organizations to develop medicines, including using its Claude models to generate 35,000 antibody designs for food allergy treatments and assisting Bristol Myers Squibb with clinical trial planning. While some executives view the firm as a partner, GSK's Chief Scientific Officer characterizes it as a competitor.

Other industry developments include a partnership between DataMEDS AI and DiaGen.ai to validate 15 cytotoxic peptides for breast cancer using a biobank of 70,000 tumor biopsies. Additionally, Schrödinger, Inc. launched the Bunsen AI co-scientist, and Recursion Pharmaceuticals reported Phase 2 data showing an 87% reduction in polyp burden for patients with familial adenomatous polyposis. Despite these gains, experts note that human clinical trials and regulatory bottlenecks remain primary hurdles to faster drug approvals.


Reported across 5 outlets
Actors
AnthropicAstraZeneca

Keep reading in the app

The full story and every source, free in the app.